463 related articles for article (PubMed ID: 19425084)
1. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
[TBL] [Abstract][Full Text] [Related]
2. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
[TBL] [Abstract][Full Text] [Related]
3. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
4. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
5. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Müller T; Renger K; Kuhn W
Arch Neurol; 2004 May; 61(5):657-60. PubMed ID: 15148140
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
[TBL] [Abstract][Full Text] [Related]
9. Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Müller T; Muhlack S
J Neural Transm (Vienna); 2009 Oct; 116(10):1253-6. PubMed ID: 19657587
[TBL] [Abstract][Full Text] [Related]
10. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease.
Müller T; Muhlack S
Clin Neuropharmacol; 2007; 30(2):101-6. PubMed ID: 17414942
[TBL] [Abstract][Full Text] [Related]
11. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
[TBL] [Abstract][Full Text] [Related]
13. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
Merello M; Nouzeilles MI; Arce GP; Leiguarda R
Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
[TBL] [Abstract][Full Text] [Related]
15. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
17. Role of homocysteine in the treatment of Parkinson's disease.
Müller T
Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels].
Lökk J
Lakartidningen; 2003 Aug; 100(35):2674-7. PubMed ID: 14531126
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
20. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]